$SLRN News

Last published 1y ago

1y agoALMS SLRNAlumis Stockholders Approve Merger with ACELYRINGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and
1y agoALMS SLRNACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesGlobeNewswireLOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today
1y agoALMS SLRNLeading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with AlumisGlobeNewswireACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the
1y agoALMS SLRNACELYRIN Reiterates Benefits of Value-Maximizing Combination with AlumisGlobeNewswireSpecial Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc.
1y agoALMS SLRNAlumis and ACELYRIN Announce Amended Merger AgreementGlobeNewswireACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on
1y agoALMS SLRNAlumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed MergerGlobeNewswireStockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote "FOR" the merger Transaction expected to be completed in second
1y agoSLRNACELYRIN Adopts Limited-Duration Stockholder Rights PlanGlobeNewswireLOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology,
1y agoALMS SLRNACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed MergerGlobeNewswireCombined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC.
1y agoALMS SLRNAlumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed MergerGlobeNewswireSOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS) ("Alumis") and ACELYRIN, INC. (NASDAQ:SLRN) ("ACELYRIN") today reaffirmed their commitment to merge in an
1y agoALMS SLRNACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis MergerGlobeNewswireAll-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on
1y agoALMS SLRNACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra BiosciencesGlobeNewswireLOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today
1y agoHEES IPG PTMN SLRNKuehn Law Encourages HEES, SLRN, PTMN, and IPG Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
1y agoNVRO SLRN TGI PTMNKuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
1y agoALMS SLRNAlumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesGlobeNewswireTopline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on
1y agoSLRNACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye DiseaseGlobeNewswireTotality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Conducted positive end
1y agoSLRNACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous LonigutamabGlobeNewswireLOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today
1y agoSLRNACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of UveitisGlobeNewswirePhase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance Company continues focus on development of subcutaneous lonigutamab in thyroid eye disease,
1y agoSLRNAcelyrin, Inc. (SLRN) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
1y agoSLRNACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent HighlightsGlobeNewswireTopline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024 Positive lonigutamab EOP2 FDA interaction completed and initiation of
2y agoSLRNACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024GlobeNewswireLOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today
2y agoSLRNACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye DiseaseGlobeNewswireExperts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 program in ﬁrst quarter of 2025 LOS
2y agoSLRNACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024GlobeNewswireLOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology,
2y agoSLRNACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive SurgeryGlobeNewswireRapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on
2y agoSLRNACELYRIN, INC. to Participate in Upcoming Investor ConferencesGlobeNewswireLOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today
2y agoSLRNAcelyrin, Inc. (SLRN) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoSLRNACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial ResultsGlobeNewswirePhase 3 trial of izokibep in hidradenitis suppurativa met primary endpoint of HiSCR75 at 12 weeks Company to prioritize development of lonigutamab; dose conﬁrmation ongoing in Phase 2 trial with plans to initiate Phase
2y agoSLRNACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024GlobeNewswireLOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today
2y agoSLRNACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024GlobeNewswireLOS ANGELES, June 05, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today
2y agoSLRNACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024GlobeNewswireLonigutamab is the first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease (TED) patients LOS ANGELES, May 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage
2y agoSLRNACELYRIN, INC. Provides Business Update and Highlights Key Upcoming MilestonesGlobeNewswireCompleted enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by end of third and
2y agoSLRNACELYRIN, INC. Announces Leadership TransitionGlobeNewswireMina Kim appointed Chief Executive Officer and to Board of Directors ACELYRIN Founder Shao-Lee Lin, M.D., Ph.D., steps down as Chief Executive Officer Shephard (Shep) Mpofu, M.D., MRCP, FRCP named Chief Medical
2y agoSLRNACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024GlobeNewswireLOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology,
2y agoSLRNACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsGlobeNewswireReported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients Achieved primary endpoint with high statistical
2y agoAVTX SLRNAvalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionGlobeNewswireAvalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of
2y agoSLRNACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye DiseaseGlobeNewswireRapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile Phase 2b/3 trial to be initiated in the second half of 2024 Conference call to review
2y agoSLRNACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic ArthritisGlobeNewswireStudy met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational trials in psoriatic arthritis Robust clinical responses achieved
2y agoSLRNACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for PatientsGlobeNewswireDose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32 Deep and consistent HiSCR responses
2y agoSLRNACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate CommunicationsGlobeNewswireHighly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies LOS ANGELES, Feb. 15, 2024 (GLOBE
2y agoSLRNACELYRIN INVESTOR DEADLINE APPROACHINGPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acelyrin, Inc. ("Acelyrin" or the "Company")...
2y agoSLRNACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their OptionsGlobeNewswireIf you suffered losses exceeding $50,000 investing in Acelyrin securities between May 4, 2023 and September 11, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at
2y agoSLRNACELYRIN INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their OptionsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acelyrin, Inc. ("Acelyrin" or the "Company")...
2y agoSLRNACELYRIN INVESTOR DEADLINE APPROACHING : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their OptionsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acelyrin, Inc. ("Acelyrin" or the "Company")...
2y agoSLRNACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their OptionsGlobeNewswireIf you suffered losses exceeding $50,000 investing in Acelyrin securities between May 4, 2023 and September 11, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at
2y agoSLRNACELYRIN INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their OptionsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acelyrin, Inc. ("Acelyrin" or the "Company")...
2y agoSLRNACELYRIN, INC. Appoints Lynn Tetrault to Board of DirectorsGlobeNewswireLOS ANGELES, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today
2y agoSLRNACELYRIN INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their OptionsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acelyrin, Inc. ("Acelyrin" or the "Company")...
2y agoSLRNACELYRIN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their OptionsGlobeNewswireIf you suffered losses exceeding $50,000 investing in Acelyrin securities between May 4, 2023 and September 11, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at
2y agoSLRNKaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)GlobeNewswireNEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc. (NASDAQ:SLRN) common stock ("Acelyrin" or the
2y agoSLRNKaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)GlobeNewswireNEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc. (NASDAQ:SLRN) common stock ("Acelyrin" or the
2y agoSLRNACELYRIN INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Acelyrin To Contact Him Directly To Discuss Their OptionsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acelyrin, Inc. ("Acelyrin" or the "Company")...